Monday, March 31, 2014

Juno Therapeutics Taps Investment Banker As CFO

Seattle-based biotechnology developer Juno Therapeutics has turned to an investment banker from Morgan Stanley, to serve as Chief Financial Officer for the company. According to Juno Therapeutics, it has named Steve Harr, M.D., as Chief Financial Officer and Head of Corporate Development. Harr was most recently Head of Global Biotech Investment Banking for Morgan Stanley, where the company said he managed more than $20 billion in financing deals and $40 billion in M&A transactions. Juno said that Harr will lead the company's financing strategy and look for "broader strategic business relationships" for the company.